Plain-English translation of NCT06383338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
The PEGASUS study is testing whether researchers can safely and practically use a test medication called or to understand how individual patients' bodies break down and metabolize cancer drugs. Young people (ages 6–25) with a new diagnosis of Hodgkin or non-Hodgkin lymphoma would take this test medication at times that match their regular cancer treatment visits, and then have their blood tested to measure how their body processes the medication. The goal is to see if this approach could one day help doctors personalize cancer treatment by knowing exactly how each patient's body handles their medicines.
Cancer drugs work differently in different people because everyone's body processes medicines at different speeds. This study wants to find out whether measuring how young patients metabolize test medications could help doctors choose the best cancer treatment doses and combinations for each individual—moving toward more personalized, precise medicine.
You likely qualify if…
You likely don't qualify if…
You would take a test medication ( or ) at times that line up with your regular hospital visits for lymphoma treatment—so you wouldn't need extra appointments. After taking the medication, a small blood sample would be drawn during your scheduled visits to measure how your body processes it. The study is very small (about 10 participants) and is designed to test whether this approach is practical and acceptable for young cancer patients.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Australia